MARC details
| 000 -LEADER |
|---|
| fixed length control field |
01807nam a2200301Ia 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
MX-MdCICY |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20250625162452.0 |
| 040 ## - CATALOGING SOURCE |
|---|
| Transcribing agency |
CICY |
| 090 ## - LOCALLY ASSIGNED LC-TYPE CALL NUMBER (OCLC); LOCAL CALL NUMBER (RLIN) |
|---|
| Classification number (OCLC) (R) ; Classification number, CALL (RLIN) (NR) |
B-20598 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
250602s9999 xx |||||s2 |||| ||und|d |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Analyzing 3D structures of the SARS-CoV-2 main protease reveals structural features of ligand binding for COVID-19 drug discovery |
| 490 0# - SERIES STATEMENT |
|---|
| Volume/sequential designation |
Drug Discovery Today, 28(10), p.103727, 2023 |
| 520 3# - SUMMARY, ETC. |
|---|
| Summary, etc. |
The severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2)main protease has an essential role in viral replication and has become a major target for coronavirus 2019 (COVID-19)drug development. Various inhibitors have been discovered or designed to bind to the main protease. The availability of more than 550 3D structures of the main protease provides a wealth of structural details on the main protease in both ligand-free and ligand-bound states. Therefore, we examined these structures to ascertain the structural features for the role of the main protease in the cleavage of polyproteins, the alternative conformations during main protease maturation, and ligand interactions in the main protease. The structural features unearthed could promote the development of COVID-19 drugs targeting the SARS-CoV-2 main protease. |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
COVID-19 |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
SARS-COV-2 |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
CONFORMATIONS |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
DRUG DISCOVERY AND DESIGN |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
INHIBITOR |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
MAIN PROTEASE |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
PROTEIN-LIGAND INTERACTIONS |
| 700 12 - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Xu, L. |
| 700 12 - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Chen, R. |
| 700 12 - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Liu, J. |
| 700 12 - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Patterson, T. A. |
| 700 12 - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Hong, H. |
| 856 40 - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
<a href="https://drive.google.com/file/d/1uv4e6Ik-LFToq--30D8tv5gWvO9pazb2/view?usp=drivesdk">https://drive.google.com/file/d/1uv4e6Ik-LFToq--30D8tv5gWvO9pazb2/view?usp=drivesdk</a> |
| Public note |
Para ver el documento ingresa a Google con tu cuenta: @cicy.edu.mx |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Clasificación local |
| Koha item type |
Documentos solicitados |
